Adage Capital Partners
SION

Adage Capital Partners’s Sionna Therapeutics SION Stock Holding History

Adage Capital Partners’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70.4M Buy
1,600,000
+1,450,000
+967% +$58M 0.1% 197
2026
Q1 		$6.01M Buy
+150,000
New +$5.72M 0.01% 760

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Adage Capital Partners's SION Position: Q2 2026 in Review

Adage Capital Partners increased its Sionna Therapeutics (SION) stake by 967% in Q2 2026, buying an estimated $58M and bringing the position to 1,600,000 shares worth $70.4M. The position accounts for 0.1% of the portfolio, ranked #197.

Adage Capital Partners first reported a position in SION in Q1 2026 and has held it in 2 quarters since. 147 funds tracked by Wall St. Rank hold SION as of Q2 2026.

  • Adage Capital Partners held 1,600,000 shares of Sionna Therapeutics worth $70.4M as of Q2 2026.
  • Adage Capital Partners bought 1,450,000 Sionna Therapeutics shares in Q2 2026, an estimated $58M.
  • Sionna Therapeutics made up 0.1% of Adage Capital Partners's portfolio in Q2 2026, its #197 holding.
  • Adage Capital Partners first reported a position in Sionna Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 147 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.